ClinicalTrials.gg
Not yet recruitingNCT07394036Updated May 5, 2026

Effect of Ipratropium Bromide on EILO

A Phase 2 interventional study of Ipratropium Bromide and Normal Saline (Placebo) in Exercise-Induced Laryngeal Obstruction and Dyspnea During Activity, sponsored by Cook Children's Health Care System. Not yet recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Cook Children's Health Care System · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.

Planned enrollment
68th of 151
50 · median 36
Started
2026
with 10 others
Phase 2
27 of 214
5 open now
Primary completion
2029-12
later than 33 of 36 live
Registered
203rd of 214
by date

Among the 214 studies in Dyspnea with a site in United States, this one is the 68th largest by planned enrollment of the 151 interventional ones that give a count, is one of 11 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 33 of the 36 other live ones, and was the 203rd registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Dyspnea with a site in United States, or all of them as a file.
02

Study summary

The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.

Read the detailed description

Many children and adolescents struggle with breathing problems during exercise. These symptoms can lead them to underperform, quit sports, and in some cases, stop being active altogether. One under-recognized cause is Exercise-Induced Laryngeal Obstruction (EILO), a narrowing of the airway at the level of the voice box. Approximately 5-8% of adolescents and 20-40% of adolescent athletes have EILO, an estimated 4-6 million nationwide. The most common treatment for EILO is Speech Therapy, with or without Physical Therapy. Where available, this requires significant time and financial commitment from patients and their families to attend therapy sessions and complete at-home exercises.

Case reports as early as 1985 have suggested aerosolized ipratropium bromide as an effective EILO treatment. One larger study could not confirm this observation. However, this study used an outcome measure with low reliability and validity, did not use a placebo control, and administered a low dose of ipratropium bromide too close to exercise.

The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with EILO following inhalation of a higher dose of nebulized ipratropium bromide with placebo. It is hypothesized that breathlessness and airway obstruction will be lower following inhalation of ipratropium bromide compared with placebo.

03

Conditions studied

  • Exercise-Induced Laryngeal Obstruction
  • Dyspnea During Activity

Browse trials for

Keywords

  • Exercise-Induced Laryngeal Obstruction
  • Shortness of Breath during Exercise
  • Ipratropium Bromide
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be diagnosed with EILO confirmed by Continuous Laryngoscopy During Exercise
  • Patients must be able to complete exercise testing
  • Patients must report dyspnea
  • Patients must have given assent with parental consent, understand all study procedures, and comply with them for the entire length of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients that do not have EILO.
  • Patients who did not undergo diagnostic CPET with CLE.
  • Patients with to atropine or its derivatives due to structural similarity with ipratropium bromide.
  • Patients with a history of atrial flutter and/or fibrillation
  • Patients taking anticholinergic medications that cannot be paused for 24 hours.
  • Unable to perform exercise tests
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of patient or parent/legally authorized representative to give written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ipratropium Bromide, then Placebo

    Participants will receive Ipratropium Bromide in their first trial and Placebo in the second trial.

    Drug: Ipratropium Bromide · Drug: Normal Saline (Placebo)

  • Experimental
    Placebo, then Ipratropium Bromide

    Participants will receive Placebo in their first trial and Ipratropium Bromide in the second trial.

    Drug: Ipratropium Bromide · Drug: Normal Saline (Placebo)

Interventions

  • DrugIpratropiumStudies of IpratropiumIpratropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nebulized Ipratropium Bromide (500µg/2.5mL); one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes

  • DrugNormal Saline (Placebo)

    3 mL of nebulized 0.9% normal saline; one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale for Dyspnea (VAS-Dyspnea)

    Shortness of breath assessed by a 0-100 Visual Analogue Scale for Dyspnea, where higher scores reflect greater breathlessness

    Time frame: Day1 and Day 2

Secondary outcomes

  1. CLE grade scoring

    Patient videos will be assessed for laryngeal obstruction by two expert reviewers. Blinded reviewers will grade the severity of glottic and supraglottic obstruction on a scale from 0 (no obstruction) to 3 (severe obstruction).

    Time frame: Day 1 and Day 2

07

Study locations

1 site
  • Cook Children's Pulmonology (Exercise Respiratory Center)
    Prosper, Texas 75078, United States
08

References and documents

Individual participant data

Plan to share: No — The investigators anticipate the institution's IRB/legal team will not approve sharing IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2029, 42 months later.

Of 23 phase 2 interventional studies under Dyspnea, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 6, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07394036
Lead sponsor
Cook Children's Health Care System
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 5, 2026

Study contacts

John M Robertson, MD
Contact
john.robertson@cookchildrens.org
682-303-4200
Andreas Kreutzer, PhD
Contact
andy.kreutzer@cookchildrens.org
682-303-7576

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ipratropium

Start the discussion